Lyon, France

Emmanuelle Monchaux

This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Dilon Technologies, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emmanuelle Monchaux: Innovator in Hemostatic Products

Introduction

Emmanuelle Monchaux is a notable inventor based in Lyons, France. She has made significant contributions to the field of medical technology, particularly in the development of hemostatic products. Her innovative approach combines advanced materials with cutting-edge printing techniques to create effective solutions for medical applications.

Latest Patents

Monchaux holds a patent for a multi-dimensional hemostatic product and the method for producing it. This invention involves a printed hemostatic product that features at least three dimensions, constructed from a stack of layers. These layers are deposited on one another, with adjacent layers joined together. A key component of the product is a hemostatic flowable, which includes non-cross-linked collagen of the fibrillar type, comprising at least 70% by weight of fibrous collagen. Additionally, the product incorporates at least one monosaccharide. The method for forming this hemostatic product utilizes a three-dimensional additive printer, showcasing the innovative use of printing technology in medical applications.

Career Highlights

Emmanuelle Monchaux is currently associated with Dilon Technologies, Inc., where she continues to advance her research and development efforts. Her work focuses on creating innovative medical solutions that address critical needs in the healthcare sector. Monchaux's dedication to her field is evident in her successful patent application and her ongoing contributions to medical technology

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…